期刊文献+

三维适形放疗联合替吉奥治疗局部晚期贲门腺癌疗效观察 被引量:10

下载PDF
导出
摘要 目的观察三维适形放疗(3D-CRT)联合替吉奥治疗局部晚期贲门腺癌的效果及不良反应。方法40例局部晚期贲门腺癌患者采用3D.CRT,1.8~2Gy/次,5次/周,总剂量60Gy/6.0~6.5周。自放射治疗开始同时口服替吉奥胶囊80mg/(m^2·d),2次/d,口服两周停一周为一周期,共口服3个周期。结果放疗结束后2个月评价近期疗效,总有效率(完全缓解十部分缓解)92.50%,临床受益率(完全缓解+部分缓解+轻微缓解)为100%。1a生存率为88.50%。不良反应主要为放射性食管炎所致的吞咽疼痛、恶心、食欲不振以及白细胞下降,多数为Ⅰ-Ⅱ级。结论3D—CRT联合替吉奥治疗局部晚期贲门癌是一种安全有效的治疗方法,值得临床应用。
出处 《山东医药》 CAS 北大核心 2011年第1期58-59,共2页 Shandong Medical Journal
  • 相关文献

参考文献3

二级参考文献18

  • 1黄河,管忠震,秦凤展,张燕军,黎莉,高亚杰,王顺金,顾康生,郭颖,孙飘扬.左亚叶酸钙联合5-氟尿嘧啶、奥沙利铂治疗晚期或复发胃、结直肠癌的Ⅱ期临床研究[J].广东医学,2005,26(11):1568-1570. 被引量:10
  • 2李鉴,张汝刚,张大为,方德康.贲门腺癌切除患者预后的多因素COX模型分析(附736例报告)[J].中华肿瘤杂志,1996,18(2):134-136. 被引量:25
  • 3邵令方 李章才 等.食管癌和贲门癌6123例外科治疗结果的分析[J].中华外科杂志,1987,25:452-452.
  • 4徐乐天 孙成孚 等.食管、贲门癌切除术后10年以上34例分析[J].中华外科杂志,1985,23:416-418.
  • 5Malet-Martino M,Martino R.Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine,UFT,S-1):a review[J].Oncologist,2002,7(4):288-323.
  • 6Tanaka F,Fukuse T,Wada H,et al.The history,mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents[J].Curr Pharm Biotechnol,2000,1(2):137-164.
  • 7Shirasaka T,Shimamato Y,Ohshimo H,et al.Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators[J].Anticancer Drugs,1996,7(5):548-557.
  • 8Shirasaka T,Tsukuda M,Inuyama Y,et al.New oral anticancer drug,TS-1 (S-1)-from bench to clinic[J].Gan To Kagaku Ryoho,2001,28(6):855-864.
  • 9Sato A,Ito T,Tomita T,et al.Chemotherapy of gastric cancer--a review of clinical trials in Japan[J].Gan To Kagaku Ryoho,2002,29(9):1522-1531.
  • 10李鉴,中华肿瘤杂志,1996年,18卷,134页

共引文献42

同被引文献53

  • 1Ikuko Miyazaki,Takashi Kawai,Youji Harada,Fuminori Moriyasu.A predictive factor for the response to S-1 plus cisplatin in gastric cancer[J].World Journal of Gastroenterology,2010,16(36):4575-4582. 被引量:8
  • 2于会明,刘运芳,于金明.三维适形放疗联合吉西他滨治疗局部晚期胰腺癌的疗效分析[J].中华放射肿瘤学杂志,2006,15(1):55-56. 被引量:30
  • 3彭柔君,董秋美,史艳侠,曹烨,周中梅,袁中玉,李苏,廖海,姜文奇.胃癌患者外周血DPD活性、5-FU血药浓度与毒性反应的相关性分析[J].癌症,2006,25(8):1039-1043. 被引量:8
  • 4Shirasaka T,Shimamoto Y,Ohshimo H,et al.Development of anovel form of an oral 5-fluorouracil derivative(S-1)directed to thepotentiation of the tumor selective cytotoxicity of 5-fluorouracil bytwo biochemical modulators[J].Anticancer Drugs,1996,7(5):548-557.
  • 5Koizumi W,Narahara H,Hara T,et al.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer(SPIRITStrial):a phaseⅢtrial[J].Lancet Oncol,2008,9(3):215-221.
  • 6Burris HA,Moore MJ,Andersen J,et al. Improvements insurvival and clinical benefit with gemcitabine as first- time therapy for patients with advanced pancreas cancer: arandomized trial [J]. ClinOncol, 1997,15 (6) : 2403- 2413.
  • 76Marantz A,Jovtis S,Almira E,et al.Phase IIstudy of gemcit-abine,5 -- fluorouracil and leucovorin in patients with pancreatic cancer.Semin Oncol,2001,28 (3 Suppl 10) : 44-497.
  • 8Kawarada Y,Yokoi H, Isaji S, et al. Modified standard pancreaticoduodenectomy for the treatment of pancreatic head cancer [ J ]. Digestion, 2009,60 (2) : 120.
  • 9Shirasaka T,Shimamato Y,Ohshimo H,et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumorselective cytotoxi- city of 5-fluorouracil by two biochemical modulators [J]. Anticancer Drugs, 1996,7 (5) : 548-557.
  • 10Yamada Y ,Yamaguchi T ,Matsumoto H, eta|. Phase 11 study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer [J]. Invest New Drugs,2012,30(4) :1690-1696.

引证文献10

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部